United States - English - NLM (National Library of Medicine)

remedyrepack inc. - metronidazole (unii: 140qmo216e) (metronidazole - unii:140qmo216e) - symptomatic trichomoniasis. metronidazole tablets are indicated for the treatment of t. vaginalis infection in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). asymptomatic trichomoniasis. metronidazole tablets are indicated in the treatment of asymptomatic  t. vaginalis infection in females when the organism is associated with endocervicitis, cervicitis, or cervical erosion. since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. treatment of asymptomatic sexual partners. t. vaginalis infection is a venereal disease. therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. the decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. in making this decision, it should be noted that there is evidence that a woman may become reinfected if her sexual partner is not treated. also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. in any event, the sexual partner should be treated with metronidazole tablets in cases of reinfection. amebiasis metronidazole tablets are indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess. in amebic liver abscess, metronidazole tablet therapy does not obviate the need for aspiration or drainage of pus. anaerobic bacterial infections. metronidazole tablets are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. indicated surgical procedures should be performed in conjunction with metronidazole tablet therapy. in a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to metronidazole tablets. intra-abdominal infections, including peritonitis, intra-abdominal abscess, and liver abscess, caused by bacteroides species including the b. fragilis group ( b. fragilis, b. distasonis, b. ovatus, b. thetaiotaomicron, b. vulgatus ), clostridium species, eubacterium species, peptococcus species, and peptostreptococcus species. skin and skin structure infections caused by bacteroides species including the b. fragilis group, clostridium species, peptococcus species, peptostreptococcus species, and fusobacterium species. gynecologic infections, including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by bacteroides species including the b. fragilis group, clostridium species, peptococcus species, peptostreptococcus species, and fusobacterium species. bacterial septicemia caused by bacteroides species including the b. fragilis group and clostridium species. bone and joint infections, (as adjunctive therapy), caused by bacteroides species including the b. fragilis group. central nervous system (cns) infections, including meningitis and brain abscess, caused by bacteroides species including the b. fragilis group. lower respiratory tract infections, including pneumonia, empyema, and lung abscess, caused by bacteroides species including the b. fragilis group. endocarditis caused by bacteroides species including the b. fragilis group. to reduce the development of drug-resistant bacteria and maintain the effectiveness of metronidazole tablets and other antibacterial drugs, metronidazole tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. metronidazole tablet are contraindicated in patients with a prior history of hypersensitivity to metronidazole or other nitroimidazole derivatives. in patients with trichomoniasis, metronidazole tablet are contraindicated during the first trimester of pregnancy (see precautions ). use of oral metronidazole is associated with psychotic reactions in alcoholic patients who were using disulfiram concurrently. do not administer metronidazole to patients who have taken disulfiram within the last two weeks (see precautions, drug interactions ). use of oral metronidazole is associated with a disulfiram-like reaction to alcohol, including abdominal cramps, nausea, vomiting, headaches, and flushing. discontinue consumption of alcohol or products containing propylene glycol during and for at least three days after therapy with metronidazole (see precautions, drug interactions ). metronidazole tablets are contraindicated in patients with cockayne syndrome. severe irreversible hepatotoxicity/acute liver failure with fatal outcomes have been reported after initiation of metronidazole in patients with cockayne syndrome (see   adverse reactions).

United States - English - NLM (National Library of Medicine)

rising pharma holdings, inc. - metronidazole (unii: 140qmo216e) (metronidazole - unii:140qmo216e) - symptomatic trichomoniasis. metronidazole tablets are indicated for the treatment of t. vaginalis infection in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). asymptomatic trichomoniasis. metronidazole tablets are indicated in the treatment of asymptomatic t. vaginalis infection in females when the organism is associated with endocervicitis, cervicitis, or cervical erosion. since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. treatment of asymptomatic sexual partners. t. vaginalis infection is a venereal disease. therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. the decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. in making this decision, it should be noted that there is evidence that a woman may become reinfected if her sexual partner is not treated. also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. in any event, the sexual partner should be treated with metronidazole tablets in cases of reinfection. amebiasis. metronidazole tablets are indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess. in amebic liver abscess, metronidazole tablets therapy does not obviate the need for aspiration or drainage of pus. anaerobic bacterial infections. metronidazole tablets are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. indicated surgical procedures should be performed in conjunction with metronidazole tablets therapy. in a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to metronidazole tablets. intra-abdominal infections, including peritonitis, intra-abdominal abscess, and liver abscess, caused by bacteroides species including the b. fragilis group (b. fragilis, b. distasonis, b. ovatus, b. thetaiotaomicron, b. vulgatus ), clostridium species, eubacterium species, peptococcus species, and peptostreptococcus species. skin and skin structure infections caused by bacteroides species including the b. fragilis group, clostridium species, peptococcus species, peptostreptococcus species, and fusobacterium species. gynecologic infections, including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by bacteroides species including the b. fragilis group, clostridium species, peptococcus species, peptostreptococcus species, and fusobacterium species. bacterial septicemia caused by bacteroides species including the b. fragilis group and clostridium species. bone and joint infections, (as adjunctive therapy), caused by bacteroides species including the b. fragilis group. central nervous system (cns) infections, including meningitis and brain abscess, caused by bacteroides species including the b. fragilis group. lower respiratory tract infections, including pneumonia, empyema, and lung abscess, caused by bacteroides species including the b. fragilis group. endocarditis caused by bacteroides species including the b. fragilis group. to reduce the development of drug-resistant bacteria and maintain the effectiveness of metronidazole tablets and other antibacterial drugs, metronidazole tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. hypersensitivity metronidazole tablets are contraindicated in patients with a prior history of hypersensitivity to metronidazole or other nitroimidazole derivatives. in patients with trichomoniasis, metronidazole tablets are contraindicated during the first trimester of pregnancy (see precautions ). psychotic reaction with disulfiram use of oral metronidazole is associated with psychotic reactions in alcoholic patients who were using disulfiram concurrently. do not administer metronidazole to patients who have taken disulfiram within the last two weeks (see precautions, drug interactions ). interaction with alcohol use of oral metronidazole is associated with a disulfiram-like reaction to alcohol, including abdominal cramps, nausea, vomiting, headaches, and flushing. discontinue consumption of alcohol or products containing propylene glycol during and for at least three days after therapy with metronidazole (see precautions, drug interactions ). cockayne syndrome metronidazole tablets are contraindicated in patients with cockayne syndrome. severe irreversible hepatotoxicity/acute liver failure with fatal outcomes have been reported after initiation of metronidazole in patients with cockayne syndrome (see adverse reactions ).

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - metronidazole (unii: 140qmo216e) (metronidazole - unii:140qmo216e) - symptomatic   trichomoniasis. metronidazole tablets, usp are indicated for the treatment of t.   vaginalis infection in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). asymptomatic   trichomoniasis. metronidazole tablets, usp are indicated in the treatment of asymptomatic t.   vaginalis infection in females when the organism is associated with endocervicitis, cervicitis, or cervical erosion. since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. treatment   of   asymptomatic   sexual   partners.   t.   vaginalis infection is a venereal disease. therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. the decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. in making this decision, it should be noted that there is evidence that a woman may become reinfected if her sexual partner is not treated. also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. in any event, the sexual partner should be treated with metronidazole tablets in cases of reinfection. amebiasis. metronidazole tablets, usp are indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess. in amebic liver abscess, metronidazole tablets therapy does not obviate the need for aspiration or drainage of pus. anaerobic   bacterial   infections. metronidazole tablets, usp are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. indicated surgical procedures should be performed in conjunction with metronidazole tablets therapy. in a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to metronidazole tablets. intra-abdominal infections, including peritonitis, intra-abdominal abscess, and liver abscess, caused by bacteroides species including the b.   fragilis group ( b.   fragilis , b.   distasonis , b.   ovatus , b.   thetaiotaomicron , b.   vulgatus ), clostridium species, eubacterium species, peptococcus   species , and peptostreptococcus species. skin and skin structure infections caused by bacteroides species including the b.   fragilis group, clostridium species, peptococcus   species , peptostreptococcus species, and fusobacterium species. gynecologic infections, including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by bacteroides species including the b.   fragilis group, clostridium species, peptococcus   species , peptostreptococcus species, and fusobacterium species. bacterial septicemia caused by bacteroides species including the b.   fragilis group and clostridium species. bone and joint infections, (as adjunctive therapy), caused by bacteroides species including the b.   fragilis group. central nervous system (cns) infections, including meningitis and brain abscess, caused by bacteroides species including the b.   fragilis group. lower respiratory tract infections, including pneumonia, empyema, and lung abscess, caused by bacteroides species including the b.   fragilis group. endocarditis caused by bacteroides species including the b.   fragilis group. to reduce the development of drug-resistant bacteria and maintain the effectiveness of metronidazole tablets and other antibacterial drugs, metronidazole tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. metronidazole tablets is contraindicated in patients with a prior history of hypersensitivity to metronidazole or other nitroimidazole derivatives. in patients with trichomoniasis, metronidazole tablets is contraindicated during the first trimester of pregnancy (see precautions ). use of oral metronidazole is associated with psychotic reactions in alcoholic patients who were using disulfiram concurrently. do not administer metronidazole to patients who have taken disulfiram within the last two weeks (see precautions, drug interactions ). use of oral metronidazole is associated with a disulfiram-like reaction to alcohol, including abdominal cramps, nausea, vomiting, headaches, and flushing. discontinue consumption of alcohol or products containing propylene glycol during and for at least three days after therapy with metronidazole (see precautions, drug interactions ). metronidazole tablets are contraindicated in patients with cockayne syndrome. severe irreversible hepatotoxicity/acute liver failure with fatal outcomes have been reported after initiation of metronidazole in patients with cockayne syndrome (see adverse reactions) .

United States - English - NLM (National Library of Medicine)

golden state medical supply, inc. - metronidazole (unii: 140qmo216e) (metronidazole - unii:140qmo216e) - symptomatic trichomoniasis.  metronidazole is indicated for the treatment of  t. vaginalis  infection in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). asymptomatic trichomoniasis. metronidazole is indicated in the treatment of asymptomatic t. vaginalis infection in females when the organism is associated with endocervicitis, cervicitis, or cervical erosion. since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. treatment of asymptomatic sexual partners. t. vaginalis infection is a venereal disease. therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. the decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. in making this decision, it should be noted that there is evidence that a woman may become reinfected if her sexual partner is not treated. also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. in any event, the sexual partner should be treated with metronidazole in cases of reinfection. amebiasis.  metronidazole is indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess. in amebic liver abscess, metronidazole therapy does not obviate the need for aspiration or drainage of pus. anaerobic bacterial infections. metronidazole is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. indicated surgical procedures should be performed in conjunction with metronidazole therapy. in a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to metronidazole. intra-abdominal infections, including peritonitis, intra-abdominal abscess, and liver abscess, caused by bacteroides species including the b. fragilis group ( b. fragilis, b. distasonis, b. ovatus, b. thetaiotaomicron, b. vulgatus ), clostridium species, eubacterium species, peptococcus species, and peptostreptococcus species. skin and skin structure infections caused by bacteroides species including the b. fragilis group, clostridium species, peptococcus  species, peptostreptococcus species, and fusobacterium species. gynecologic infections, including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by  bacteroides  species including the  b. fragilis  group,  clostridium  species,  peptococcus  species,  peptostreptococcus  species, and  fusobacterium  species. bacterial septicemia caused by bacteroides species including the b. fragilis group and clostridium species. bone and joint infections, (as adjunctive therapy), caused by  bacteroides  species including the  b. fragilis  group. central nervous system (cns) infections, including meningitis and brain abscess, caused by bacteroides species including the b. fragilis group. lower respiratory tract infections, including pneumonia, empyema, and lung abscess, caused by bacteroides species including the b. fragilis group. endocarditis caused by bacteroides species including the b. fragilis group. to reduce the development of drug-resistant bacteria and maintain the effectiveness of metronidazole and other antibacterial drugs, metronidazole should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. metronidazole tablets are contraindicated in patients with a prior history of hypersensitivity to metronidazole or other nitroimidazole derivatives. in patients with trichomoniasis, metronidazole tablets are contraindicated during the first trimester of pregnancy (see  precautions ). use of oral metronidazole is associated with a disulfiram-like reaction to alcohol, including abdominal cramps, nausea, vomiting, headaches, and flushing. discontinue consumption of alcohol or products containing propylene glycol during and for at least three days after therapy with metronidazole (see precautions, drug interactions ). metronidazole tablets, usp are contraindicated in patients with cockayne syndrome. severe irreversible hepatotoxicity/acute liver failure with fatal outcomes have been reported after initiation of metronidazole in patients with cockayne syndrome (see ​adverse reactions ​)

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - metronidazole (unii: 140qmo216e) (metronidazole - unii:140qmo216e) - symptomatic   trichomoniasis. metronidazole tablets, usp are indicated for the treatment of t.   vaginalis infection in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). asymptomatic   trichomoniasis. metronidazole tablets, usp are indicated in the treatment of asymptomatic t.   vaginalis infection in females when the organism is associated with endocervicitis, cervicitis, or cervical erosion. since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. treatment   of   asymptomatic   sexual   partners.   t.   vaginalis infection is a venereal disease. therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. the decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. in making this decision, it should be noted that there is evidence that a woman may become reinfected if her sexual partner is not treated. also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. in any event, the sexual partner should be treated with metronidazole tablets in cases of reinfection. amebiasis. metronidazole tablets, usp are indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess. in amebic liver abscess, metronidazole tablets therapy does not obviate the need for aspiration or drainage of pus. anaerobic   bacterial   infections. metronidazole tablets, usp are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. indicated surgical procedures should be performed in conjunction with metronidazole tablets therapy. in a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to metronidazole tablets. intra-abdominal infections, including peritonitis, intra-abdominal abscess, and liver abscess, caused by bacteroides species including the b.   fragilis group ( b.   fragilis , b.   distasonis , b.   ovatus , b.   thetaiotaomicron , b.   vulgatus ), clostridium species, eubacterium species, peptococcus   species , and peptostreptococcus species. skin and skin structure infections caused by bacteroides species including the b.   fragilis group, clostridium species, peptococcus   species , peptostreptococcus species, and fusobacterium species. gynecologic infections, including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by bacteroides species including the b.   fragilis group, clostridium species, peptococcus   species , peptostreptococcus species, and fusobacterium species. bacterial septicemia caused by bacteroides species including the b.   fragilis group and clostridium species. bone and joint infections, (as adjunctive therapy), caused by bacteroides species including the b.   fragilis group. central nervous system (cns) infections, including meningitis and brain abscess, caused by bacteroides species including the b.   fragilis group. lower respiratory tract infections, including pneumonia, empyema, and lung abscess, caused by bacteroides species including the b.   fragilis group. endocarditis caused by bacteroides species including the b.   fragilis group. to reduce the development of drug-resistant bacteria and maintain the effectiveness of metronidazole tablets and other antibacterial drugs, metronidazole tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. metronidazole tablets is contraindicated in patients with a prior history of hypersensitivity to metronidazole or other nitroimidazole derivatives. in patients with trichomoniasis, metronidazole tablets is contraindicated during the first trimester of pregnancy (see precautions ). use of oral metronidazole is associated with psychotic reactions in alcoholic patients who were using disulfiram concurrently. do not administer metronidazole to patients who have taken disulfiram within the last two weeks (see precautions, drug interactions ). use of oral metronidazole is associated with a disulfiram-like reaction to alcohol, including abdominal cramps, nausea, vomiting, headaches, and flushing. discontinue consumption of alcohol or products containing propylene glycol during and for at least three days after therapy with metronidazole (see precautions, drug interactions ). metronidazole tablets are contraindicated in patients with cockayne syndrome. severe irreversible hepatotoxicity/acute liver failure with fatal outcomes have been reported after initiation of metronidazole in patients with cockayne syndrome (see adverse reactions) .

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - metronidazole (unii: 140qmo216e) (metronidazole - unii:140qmo216e) - symptomatic trichomoniasis. metronidazole tablets are indicated for the treatment of t. vaginalis infection in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). asymptomatic trichomoniasis . metronidazole tablets are indicated in the treatment of asymptomatic t. vaginalis infection in females when the organism is associated with endocervicitis, cervicitis, or cervical erosion. since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. treatment of asymptomatic sexual partners.  t. vaginalis infection is a venereal disease. therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. the decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. in making this decision, it should be noted that there is evidence that a woman may become reinfected if her sexual partner is not treated. also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. in any event, the sexual partner should be treated with metronidazole tablets in cases of reinfection. amebiasis. metronidazole tablets are indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess. in amebic liver abscess, metronidazole tablet therapy does not obviate the need for aspiration or drainage of pus. anaerobic bacterial infections. metronidazole tablets are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. indicated surgical procedures should be performed in conjunction with metronidazole tablet therapy. in a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to metronidazole tablets. intra-abdominal infections, including peritonitis, intra-abdominal abscess, and liver abscess, caused by bacteroides species including the b. fragilis  group (b. fragilis, b. distasonis, b. ovatus, b. thetaiotaomicron, b. vulgatus ), clostridium species, eubacterium species, peptococcus species, and peptostreptococcus species. skin and skin structure infections caused by bacteroides species including the b. fragilis group, clostridium species, peptococcus species, peptostreptococcus species, and fusobacterium species. gynecologic infections, including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by bacteroides species including the b. fragilis group, clostridium species , peptococcus species , peptostreptococcus species , and fusobacterium species . bacterial septicemia caused by bacteroides species including the b. fragilis group and  clostridium species.  bone and joint infections, (as adjunctive therapy), caused by bacteroides species including the b. fragilis group. central nervous system (cns) infections, including meningitis and brain abscess, caused by bacteroides species including the b. fragilis group. lower respiratory tract infections, including pneumonia, empyema, and lung abscess, caused by bacteroides species including the b. fragili s group. endocarditis caused by bacteroides species including the b. fragilis group. to reduce the development of drug-resistant bacteria and maintain the effectiveness of metronidazole and other antibacterial drugs, metronidazole tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. metronidazole tablets are contraindicated in patients with a prior history of hypersensitivity to metronidazole or other nitroimidazole derivatives. in patients with trichomoniasis, metronidazole tablets are contraindicated during the first trimester of pregnancy (see precautions ). use of oral metronidazole is associated with psychotic reactions in alcoholic patients who were using disulfiram concurrently. do not administer metronidazole to patients who have taken disulfiram within the last two weeks (see precautions , drug interactions ). use of oral metronidazole is associated with a disulfiram-like reaction to alcohol, including abdominal cramps, nausea, vomiting, headaches, and flushing. discontinue consumption of alcohol or products containing propylene glycol during and for at least three days after therapy with metronidazole (see precautions, drug interactions ). cockayne syndrome metronidazole tablets are contraindicated in patients with cockayne syndrome. severe irreversible hepatotoxicity/acute liver failure with fatal outcomes have been reported after initiation of metronidazole in patients with cockayne syndrome (see adverse reactions ).

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - metronidazole (unii: 140qmo216e) (metronidazole - unii:140qmo216e) - symptomatic   trichomoniasis. metronidazole tablets, usp are indicated for the treatment of t.   vaginalis infection in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). asymptomatic   trichomoniasis. metronidazole tablets, usp are indicated in the treatment of asymptomatic t.   vaginalis infection in females when the organism is associated with endocervicitis, cervicitis, or cervical erosion. since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. treatment   of   asymptomatic   sexual   partners.   t.   vaginalis infection is a venereal disease. therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. the decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. in making this decision, it should be noted that there is evidence that a woman may become reinfected if her sexual partner is not treated. also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. in any event, the sexual partner should be treated with metronidazole tablets in cases of reinfection. amebiasis. metronidazole tablets, usp are indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess. in amebic liver abscess, metronidazole tablets therapy does not obviate the need for aspiration or drainage of pus. anaerobic   bacterial   infections. metronidazole tablets, usp are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. indicated surgical procedures should be performed in conjunction with metronidazole tablets therapy. in a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to metronidazole tablets. intra-abdominal infections, including peritonitis, intra-abdominal abscess, and liver abscess, caused by bacteroides species including the b.   fragilis group ( b.   fragilis , b.   distasonis , b.   ovatus , b.   thetaiotaomicron , b.   vulgatus ), clostridium species, eubacterium species, peptococcus   species , and peptostreptococcus species. skin and skin structure infections caused by bacteroides species including the b.   fragilis group, clostridium species, peptococcus   species , peptostreptococcus species, and fusobacterium species. gynecologic infections, including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by bacteroides species including the b.   fragilis group, clostridium species, peptococcus   species , peptostreptococcus species, and fusobacterium species. bacterial septicemia caused by bacteroides species including the b.   fragilis group and clostridium species. bone and joint infections, (as adjunctive therapy), caused by bacteroides species including the b.   fragilis group. central nervous system (cns) infections, including meningitis and brain abscess, caused by bacteroides species including the b.   fragilis group. lower respiratory tract infections, including pneumonia, empyema, and lung abscess, caused by bacteroides species including the b.   fragilis group. endocarditis caused by bacteroides species including the b.   fragilis group. to reduce the development of drug-resistant bacteria and maintain the effectiveness of metronidazole tablets and other antibacterial drugs, metronidazole tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. metronidazole tablets is contraindicated in patients with a prior history of hypersensitivity to metronidazole or other nitroimidazole derivatives. in patients with trichomoniasis, metronidazole tablets is contraindicated during the first trimester of pregnancy (see precautions ). use of oral metronidazole is associated with psychotic reactions in alcoholic patients who were using disulfiram concurrently. do not administer metronidazole to patients who have taken disulfiram within the last two weeks (see precautions, drug interactions ). use of oral metronidazole is associated with a disulfiram-like reaction to alcohol, including abdominal cramps, nausea, vomiting, headaches, and flushing. discontinue consumption of alcohol or products containing propylene glycol during and for at least three days after therapy with metronidazole (see precautions, drug interactions ).

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - metronidazole (unii: 140qmo216e) (metronidazole - unii:140qmo216e) - symptomatic trichomoniasis. metronidazole tablets are indicated for the treatment of t. vaginalis infection in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). asymptomatic trichomoniasis. metronidazole tablets are indicated in the treatment of asymptomatic t. vaginalis infection in females when the organism is associated with endocervicitis, cervicitis, or cervical erosion. since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. treatment of asymptomatic sexual partners. t. vaginalis infection is a venereal disease. therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. the decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. in making this decision, it should be noted that there is evidence that a woman may become reinfected if her sexual partner is not treated. also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. in any event, the sexual partner should be treated with metronidazole tablets in cases of reinfection. amebiasis. metronidazole tablets are indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess. in amebic liver abscess, metronidazole tablets therapy does not obviate the need for aspiration or drainage of pus. anaerobic bacterial infections. metronidazole tablets are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. indicated surgical procedures should be performed in conjunction with metronidazole tablets therapy. in a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to metronidazole tablets. intra-abdominal infections, including peritonitis, intra-abdominal abscess, and liver abscess, caused by bacteroides species including the b. fragilis group ( b. fragilis, b. distasonis, b. ovatus, b. thetaiotaomicron, b. vulgatus ), clostridium species, eubacterium species, peptococcus species, and peptostreptococcus species. skin and skin structure infections caused by bacteroides species including the b. fragilis group, clostridium species, peptococcus species, peptostreptococcus species, and fusobacterium species. gynecologic infections, including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by bacteroides species including the b. fragilis group, clostridium species, peptococcus species, peptostreptococcus species, and fusobacterium species. bacterial septicemia caused by bacteroides species including the b. fragilis group and clostridium species. bone and joint infections, (as adjunctive therapy), caused by bacteroides species including the b. fragilis group. central nervous system (cns) infections, including meningitis and brain abscess, caused by bacteroides species including the b. fragilis group. lower respiratory tract infections, including pneumonia, empyema, and lung abscess, caused by bacteroides species including the b. fragilis group. endocarditis caused by bacteroides species including the b. fragilis group. to reduce the development of drug-resistant bacteria and maintain the effectiveness of metronidazole tablets and other antibacterial drugs, metronidazole tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. hypersensitivity metronidazole tablets are contraindicated in patients with a prior history of hypersensitivity to metronidazole or other nitroimidazole derivatives. in patients with trichomoniasis, metronidazole tablets are contraindicated during the first trimester of pregnancy (see precautions ). psychotic reaction with disulfiram use of oral metronidazole is associated with psychotic reactions in alcoholic patients who were using disulfiram concurrently. do not administer metronidazole to patients who have taken disulfiram within the last two weeks (see precautions, drug interactions ). interaction with alcohol use of oral metronidazole is associated with a disulfiram-like reaction to alcohol, including abdominal cramps, nausea, vomiting, headaches, and flushing. discontinue consumption of alcohol or products containing propylene glycol during and for at least three days after therapy with metronidazole (see precautions, drug interactions ). cockayne syndrome metronidazole tablets are contraindicated in patients with cockayne syndrome. severe irreversible hepatotoxicity/acute liver failure with fatal outcomes have been reported after initiation of metronidazole in patients with cockayne syndrome (see adverse reactions ).

United States - English - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - metronidazole (unii: 140qmo216e) (metronidazole - unii:140qmo216e) - symptomatic   trichomoniasis. metronidazole tablets, usp are indicated for the treatment of t.   vaginalis infection in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). asymptomatic   trichomoniasis. metronidazole tablets, usp are indicated in the treatment of asymptomatic t.   vaginalis infection in females when the organism is associated with endocervicitis, cervicitis, or cervical erosion. since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. treatment   of   asymptomatic   sexual   partners.   t.   vaginalis infection is a venereal disease. therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. the decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. in making this decision, it should be noted that there is evidence that a woman may become reinfected if her sexual partner is not treated. also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. in any event, the sexual partner should be treated with metronidazole tablets in cases of reinfection. amebiasis. metronidazole tablets, usp are indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess. in amebic liver abscess, metronidazole tablets therapy does not obviate the need for aspiration or drainage of pus. anaerobic   bacterial   infections. metronidazole tablets, usp are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. indicated surgical procedures should be performed in conjunction with metronidazole tablets therapy. in a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to metronidazole tablets. intra-abdominal infections, including peritonitis, intra-abdominal abscess, and liver abscess, caused by bacteroides species including the b.   fragilis group ( b.   fragilis , b.   distasonis , b.   ovatus , b.   thetaiotaomicron , b.   vulgatus ), clostridium species, eubacterium species, peptococcus   species , and peptostreptococcus species. skin and skin structure infections caused by bacteroides species including the b.   fragilis group, clostridium species, peptococcus   species , peptostreptococcus species, and fusobacterium species. gynecologic infections, including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by bacteroides species including the b.   fragilis group, clostridium species, peptococcus   species , peptostreptococcus species, and fusobacterium species. bacterial septicemia caused by bacteroides species including the b.   fragilis group and clostridium species. bone and joint infections, (as adjunctive therapy), caused by bacteroides species including the b.   fragilis group. central nervous system (cns) infections, including meningitis and brain abscess, caused by bacteroides species including the b.   fragilis group. lower respiratory tract infections, including pneumonia, empyema, and lung abscess, caused by bacteroides species including the b.   fragilis group. endocarditis caused by bacteroides species including the b.   fragilis group. to reduce the development of drug-resistant bacteria and maintain the effectiveness of metronidazole tablets and other antibacterial drugs, metronidazole tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. metronidazole tablets is contraindicated in patients with a prior history of hypersensitivity to metronidazole or other nitroimidazole derivatives. in patients with trichomoniasis, metronidazole tablets is contraindicated during the first trimester of pregnancy (see precautions ). use of oral metronidazole is associated with psychotic reactions in alcoholic patients who were using disulfiram concurrently. do not administer metronidazole to patients who have taken disulfiram within the last two weeks (see precautions, drug interactions ). use of oral metronidazole is associated with a disulfiram-like reaction to alcohol, including abdominal cramps, nausea, vomiting, headaches, and flushing. discontinue consumption of alcohol or products containing propylene glycol during and for at least three days after therapy with metronidazole (see precautions, drug interactions ). metronidazole tablets are contraindicated in patients with cockayne syndrome. severe irreversible hepatotoxicity/acute liver failure with fatal outcomes have been reported after initiation of metronidazole in patients with cockayne syndrome (see adverse reactions) .

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - metronidazole (unii: 140qmo216e) (metronidazole - unii:140qmo216e) - symptomatic trichomoniasis. metronidazole tablets are indicated for the treatment of t. vaginalis infection in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). asymptomatic trichomoniasis . metronidazole tablets are indicated in the treatment of asymptomatic t. vaginalis infection in females when the organism is associated with endocervicitis, cervicitis, or cervical erosion. since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. treatment of asymptomatic sexual partners.  t. vaginalis infection is a venereal disease. therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. the decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. in making this decision, it should be noted that there is evidence that a woman may become reinfected if her sexual partner is not treated. also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. in any event, the sexual partner should be treated with metronidazole tablets in cases of reinfection. amebiasis. metronidazole tablets are indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess. in amebic liver abscess, metronidazole tablet therapy does not obviate the need for aspiration or drainage of pus. anaerobic bacterial infections. metronidazole tablets are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. indicated surgical procedures should be performed in conjunction with metronidazole tablet therapy. in a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to metronidazole tablets. intra-abdominal infections, including peritonitis, intra-abdominal abscess, and liver abscess, caused by bacteroides species including the b. fragilis  group (b. fragilis, b. distasonis, b. ovatus, b. thetaiotaomicron, b. vulgatus ), clostridium species, eubacterium species, peptococcus species, and peptostreptococcus species. skin and skin structure infections caused by bacteroides species including the b. fragilis group, clostridium species, peptococcus species, peptostreptococcus species, and fusobacterium species. gynecologic infections, including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by bacteroides species including the b. fragilis group, clostridium species , peptococcus species , peptostreptococcus species , and fusobacterium species . bacterial septicemia caused by bacteroides species including the b. fragilis group and  clostridium species.  bone and joint infections, (as adjunctive therapy), caused by bacteroides species including the b. fragilis group. central nervous system (cns) infections, including meningitis and brain abscess, caused by bacteroides species including the b. fragilis group. lower respiratory tract infections, including pneumonia, empyema, and lung abscess, caused by bacteroides species including the b. fragili s group. endocarditis caused by bacteroides species including the b. fragilis group. to reduce the development of drug-resistant bacteria and maintain the effectiveness of metronidazole and other antibacterial drugs, metronidazole tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. metronidazole tablets are contraindicated in patients with a prior history of hypersensitivity to metronidazole or other nitroimidazole derivatives. in patients with trichomoniasis, metronidazole tablets are contraindicated during the first trimester of pregnancy (see precautions ). use of oral metronidazole is associated with psychotic reactions in alcoholic patients who were using disulfiram concurrently. do not administer metronidazole to patients who have taken disulfiram within the last two weeks (see precautions , drug interactions ). use of oral metronidazole is associated with a disulfiram-like reaction to alcohol, including abdominal cramps, nausea, vomiting, headaches, and flushing. discontinue consumption of alcohol or products containing propylene glycol during and for at least three days after therapy with metronidazole (see precautions, drug interactions ). cockayne syndrome metronidazole tablets are contraindicated in patients with cockayne syndrome. severe irreversible hepatotoxicity/acute liver failure with fatal outcomes have been reported after initiation of metronidazole in patients with cockayne syndrome (see adverse reactions ).